====== Nuclear Science Seminar Speaker Schedule Sign Up ======
[[public:Current Schedule]]
Speaker = **[[https://www.uab.edu/medicine/radiology/faculty/research-faculty/profile/lapi|Prof. Suzanne E. Lapi]]** of [[https://www.lapilab.com/|University of Alabama at Birmingham]]
Host = Domnanich, Katharina [[domnanic@frib.msu.edu]]
When = 2025-09-10 Wednesday
Where = FRIB 1300
Please feel free to sign up below, but note that some slots may need to be re-assigned to accommodate those with a specific need to meet the speaker. If this happens, the Admin or Speaker Host will reach out to you via email.
The theranostic concept where similar or identical radiopharmaceuticals are used for tandem imaging and therapeutic strategies has been paradigm shifting for the field of nuclear medicine. The theranostic isotope pairing in FDA approved radiopharmaceuticals typically consists of two different radionuclides, for example 68Ga for imaging and 177Lu for therapy. A disadvantage of using this pair is that 68Ga and 177Lu are chemically different, which may result in different pharmacokinetics of radiopharmaceuticals labelled with these two compounds. The ideal theranostic pair would include radioisotopes of the same element (isotope pairs) but with different emissions (i.e., one suitable for diagnosis and the other for therapy). To this end, our group has focused on the production of 43Sc and 47Sc as a true matched theranostic pair for imaging and therapy as well as methods for production of 203Pb as an imaging analogue for the therapeutic isotope 212Pb. More recent work has focused on imaging analogues of F-block radionuclides including 155Tb and 140Nd, Additional research has developed chemistry to incorporate these radioisotopes into new imaging radiopharmaceuticals for preclinical and eventually clinical imaging studies.Relevant background with commentary from Speaker: * [[https://doi.org/10.1016/S1470-2045(24)00030-5|Recent advances and impending challenges for the radiopharmaceutical sciences in oncology]]